Truvian Partnered With Siemens Healthineers

The diagnostics firm will leverage Siemens' technical and commercial expertise to scale its blood-testing platform.

Updated on Oct. 1, 2026 in Healthcare

Truvian Partnered With Siemens Healthineers

Live Poll

Would you prefer to have routine diagnostic blood tests done at a local pharmacy?

Truvian has entered a strategic partnership with Siemens Healthineers to expand access to diagnostic testing nationwide. The collaboration will combine Truvian's automated testing technology with the global reach and resources of Siemens Healthineers.

Why it matters

This partnership aims to integrate Truvian's diagnostic platform into a wider network of clinical research sites, retail pharmacies, and doctors' offices. By scaling distribution through an industry leader, the move is intended to broaden patient access to efficient diagnostic services.

The TruVerus system provides diagnostic results in approximately 30 minutes. It currently holds FDA clearance for a kidney panel and nine specific metabolic, cardiovascular, and liver health analyses.

The players

Truvian

This diagnostic company develops automated laboratory systems designed for chemistry, immunoassay, and hematology testing.

Siemens Healthineers

This global medical technology company provides a wide range of imaging, diagnostic, and laboratory equipment to healthcare providers worldwide.

The details

Truvian's TruVerus diagnostic system utilizes a combination of automated pipettors, cell imagers, absorbance readers, bead scanners, and onboard centrifuges. The platform operates using single-use consumable reagent kits to perform chemistry, immunoassay, and hematology testing.

December 2025: The FDA cleared the TruVerus instrument and a kidney panel.
January 2026: The FDA cleared complete blood counts and nine health analyses.
October 2026: The partnership between Truvian and Siemens Healthineers was announced.

Market Landscape

This partnership signals a trend toward consolidation in the diagnostics sector as established industry giants seek to integrate innovative, localized testing technology into their existing portfolios. The deal mirrors the expansion strategy observed in the 2026 Siemens Healthineers agreement with Novo, further solidifying the firm's influence over clinical diagnostic pathways.

Patients may soon find faster diagnostic testing options at local pharmacies and doctors' offices as the TruVerus platform scales. These clinical-grade results, available in roughly 30 minutes, could reduce the need for repeat visits or long waits associated with traditional laboratory processing.

The takeaway

The move toward rapid, point-of-care testing represents a shift in how medical diagnostics are delivered and accessed by the public. Patients should monitor whether their local healthcare providers adopt these integrated systems to streamline their routine health screenings.